Mirtazapine for fibromyalgia in adults
References
Additional references
Anttila SAK, Leinonen EVJ. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Review 2000;7:249‐64. [DOI: 10.1111/j.1527‐3458.2001.tb00198.x]
Arnold P, Vuadens P, Kuntzer T, Gobelet C, Deriaz O. Mirtazapine decreases the pain feeling in healthy participants. Clinical Journal of Pain 2008;24(2):116‐9. [DOI: 10.1097/AJP.0b013e318159f94a]
Arnold LM, Fan J, Russell IJ, Yunus MB, Khan MA, Kushner I, et al. The fibromyalgia family study: a genome wide linkage scan study. Arthritis and Rheumatism 2013;65:1122‐8. [DOI: 10.1002/art.37842]
Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders 2007;8:27. [DOI: 10.1186/1471‐2474‐8‐27]
Chang MH, Hsu JW, Huang KL, Su TP, Bai YM, Li CT, et al. Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study. Journal of Pain 2015;16:895‐902. [DOI: 10.1016/j.jpain.2015.06.004]
Choi CJ, Knutsen R, Oda K, Fraser GE, Knutsen S. The association between incident self‐reported fibromyalgia and nonpsychiatric factors: 25‐years follow‐up of the Adventist Health Study. Journal of Pain 2011;11:994‐1103. [DOI: 10.1016/j.jpain.2010.01.267]
Cohen J. Statistical Power Analysis for the Behavioral Sciences. Erlbaum, 1988.
Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, Mavros P, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real‐world therapies. Rheumatology (Oxford) 2015;54(2):270‐7. [DOI: 10.1093/rheumatology/keu332]
Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia pain in adults. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012188.pub2]
Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Annals of Clinical Psychiatry 2012;24:215‐24. [PUBMED: 22860241]
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005]
Effective Practice, Organisation of Care (EPOC). 23. Worksheets for preparing a Summary of Findings using GRADE. Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services. Available at: epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 3 March 2017)2015.
Fayers PM, Hays RD. Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality of Life Research 2014;23:1‐4. [DOI: 10.1007/s11136‐013‐0443‐4]
Fitzcharles MA, Ste‐Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Research and Management 2013;18:119‐26. [DOI: 10.1155/2013/918216]
Forseth KO, Husby G, Gran JT, Førre O. Prognostic factors for the development of fibromyalgia in women with self reported musculoskeletal pain. Journal of Rheumatology 1999;26:2458–67. [PUBMED: 10555910]
Freynhagen R, Muth‐Selbach U, Lipfert P, Stevens MF, Zacharowski K, Tölle TR, et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Current Medical Research and Opinion 2006;22(2):257‐64. [DOI: 10.1185/030079906X80486]
Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta‐analyses. International Clinical Psychopharmacology 2005;20:49‐52. [PUBMED: 15602117]
Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383‐94. [DOI: 10.1016/j.jclinepi.2011.03.017]
Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso‐Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66:151‐7.
Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology 2013;66:158‐72.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017]
Häuser W, Kosseva M, Üceyler N, Klose P, Sommer C. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta‐analysis. Arthritis Care and Research 2011;63:808‐20. [DOI: 10.1002/acr.20328]
Häuser W, Jung E, Erbslöh‐Möller B, Gesmann M, Kühn‐Becker H, Petermann F, et al. German fibromyalgia consumer reports. Benefits and harms of fibromyalgia syndrome therapies. Schmerz 2012;26(2):150‐9. [DOI: 10.1007/s00482‐012‐1161‐5]
Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010292]
Häuser W, Galek A, Erbslöh‐Möller B, Köllner V, Kühn‐Becker H, Langhorst J, et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain 2013;154(8):1216‐23. [DOI: 10.1016/j.pain.2013.03.034]
Häuser W, Ablin J, Fitzcharles MA, Littlejohn J, Luciano JV, et al. Fibromyalgia. Nature Reviews Disease Primers 2015;2:15022. [DOI: 10.1038/nrdp.2015.22]
Häuser W, Klose P, Welsch P, Petzke F, Nothacker M, Kopp I. Methodology of the development of the updated LONTS guidelines for long‐term administration of opioids in noncancer pain. Schmerz 2015;29:8‐34. [DOI: 10.1007/s00482‐014‐1462‐y]
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [DOI: org/10.1016/0197‐2456(95)00134‐4]
Kent JM. SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355(9219):911‐8. [DOI: 10.1016/S0140‐6736(99)11381‐3]
L'Abbé KA, Detsky AS, O'Rourke K. Meta‐analysis in clinical research. Annals of Internal Medicine 1987;107(2):224‐33. [DOI: 10.7326/0003‐4819‐107‐2‐224]
Lange M, Petermann F. Influence of depression on fibromyalgia: a systematic review. Schmerz 2010;24(4):326‐33. [DOI: 10.1007/s00482‐010‐0937‐8]
Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schünemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;2:81. [DOI: 10.1186/2046‐4053‐2‐81]
Lee YH, Choi SJ, Ji JD, Song GG. Candidate gene studies of fibromyalgia: a systematic review and meta‐analysis. Rheumatology International 2012;32(2):417‐26. [DOI: 10.1007/s00296‐010‐1678‐9]
Lee YC, Lu B, Boire G, Haraoui B, Hitchon CA, Pope JE, et al. Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Annals of Rheumatic Diseases 2013;72(6):949–54. [DOI: 10.1136/annrheumdis‐2012‐201506]
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3]
Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Annals of Rheumatic Diseases 2017;76(2):318‐28. [DOI: 10.1136/annrheumdis‐2016‐209724]
Martínez‐Martínez LA, Mora T, Vargas A, Fuentes‐Iniestra M, Martínez‐Lavín M. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case‐control studies. Journal of Clinical Rheumatology 2014;20(3):146‐50. [DOI: 10.1097/RHU.0000000000000089]
McQuay HJ, Moore RA. An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998.
Montgomery SA. Safety of mirtazapine: a review. International Clinical Psychopharmacology 1995;10 Suppl 4:37‐45.
Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7]
Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5]
Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2]
Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011]
Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039]
Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805]
Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers‐needed‐to‐treat analyses‐‐do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo‐controlled chronic low back pain trials. Pain 2010;151(3):592‐7. [DOI: 10.1016/j.pain.2010.07.013]
Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta‐analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982‐9. [DOI: 10.1016/j.pain.2010.11.030]
Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post‐operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427‐32. [DOI: 10.1097/EJA.0b013e328343c569]
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004]
Moore RA, Straube S, Aldington D. Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. [DOI: 10.1111/anae.12148]
Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690]
Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79‐94. [DOI: 10.1111/papr.12050]
Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions‐‐individual patient data responder analysis. European Journal of Pain 2014;18(1):67‐75. [DOI: 10.1002/j.1532‐2149.2013.00341.x]
Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord‐Trøndelag Health Study. Arthritis Care and Research 2010;62(5):611‐7. [DOI: 10.1002/acr.20118]
Mork PG, Nilsen TI. Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis and Rheumatism 2012;64(1):281‐4. [DOI: 10.1002/art.33346]
O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6‐15. [DOI: 10.1111/j.1526‐4637.2009.00685.x]
PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 28 February 2017).
Peloso PM, Moore RA, Chen WJ, Lin HY, Gates DF, Straus WL, et al. Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial. Scandinavian Journal of Pain 2016;13(10):175‐81. [DOI: 10.1016/j.sjpain.2016.07.002]
Petzke F, Brückle W, Eidmann U, Heldmann P, Köllner V, Kühn T, et al. General principles and coordination of care and patient education in fibromyalgia syndrome. Updated guideline 2017 and review of systematic reviews [Allgemeine Behandlungsgrundsätze, Versorgungskoordination und Patientenschulung beim Fibromyalgiesyndrom: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten]. Schmerz 2017;31(3):246‐54.
Queiroz LP. Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports 2013;17(8):356. [DOI: 10.1007/s11916‐013‐0356‐5]
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Samborski W, Lezańska‐Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004;37(4):168‐70. [DOI: 10.1055/s‐2004‐827172]
Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Häuser W. Opioids in chronic osteoarthritis pain. A systematic review and meta‐analysis of efficacy, tolerability and safety in randomized placebo‐controlled studies of at least 4 weeks duration. Schmerz 2015;29(1):47‐59. [DOI: 10.1007/s00482‐014‐1451‐1]
Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266‐75. [DOI: 10.1111/j.1365‐2125.2008.03200]
Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia‐‐responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471‐2474‐11‐150]
Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders 2011;12:125. [DOI: 10.1186/1471‐2474‐12‐125]
Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One 2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491]
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163‐96. [DOI: 10.1016/S0140‐6736(12)61729‐2]
Remerone anyone?. forums.webmd.com/3/fibromyalgia‐exchange/forum/3685. Accessed 2 February 2017.
Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2]
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis and Rheumatism 1990;33(2):160‐72. [DOI: 10.1002/art.1780330203]
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62(5):600‐10. [DOI: 10.1002/acr.20140]
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. Journal of Rheumatology 2011;38(6):1113‐22. [DOI: 10.3899/jrheum.100594]
Wolfe F, Häuser W, Hassett AL, Katz RS, Walitt BT. The development of fibromyalgia ‐ I: Examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 2011;152(2):291‐9. [DOI: 10.1016/j.pain.2010.09.027]
Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research 2013;645(5):777‐85. [DOI: 10.1002/acr.21931]
Wolfe F, Walitt BT, Häuser W. What is fibromyalgia, how is it diagnosed and what does it really mean?. Arthritis Care and Research 2014;66(7):969‐71. [DOI: 10.1002/acr.22207]
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism 2016;46(3):319‐29. [DOI: 10.1016/j.semarthrit.2016.08.012]
Üceyler N, Häuser W, Sommer C. Systematic review with meta‐analysis: cytokines in fibromyalgia syndrome. BMC Musculoskeletal Disorders 2011;12:245. [DOI: 10.1186/1471‐2474‐12‐245]
Üçeyler N, Sommer C, Walitt B, Häuser W. Anticonvulsants for fibromyalgia. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010782]
Üçeyler N, Burgmer M, Friedel E, Greiner W, Petzke F, Sarholz M, et al. Etiology and pathophysiology of fibromyalgia syndrome: Updated guideline 2017, overview of systematic reviews and review of studies on small fiber pathology in subgroups of fibromyalgia syndrome [Ätiologie und Pathophysiologie des Fibromyalgiesyndroms: Aktualisierte Leitlinie 2017 und Übersicht von systematischen Übersichtsarbeiten sowie eine Übersicht über Studien zur Kleinfaserpathologie bei Subgruppen des FMS]. Schmerz 2017;31(3):239‐45.
